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INTRODUCTION 
 
Fine Needle Biopsy (FNB) is defined as using a fine needle to remove a 
sample of cells from a suspicious mass for diagnostic purposes. 
Fine needle cytology has proven to be an effective first line diagnostic tool 
in evaluating palpable thyroid lesions. It allows better selection of the 
patients who need to undergo a surgical procedure, and also helps in 
deciding what surgery to be performed. It can be performed quickly and 
painlessly in the outpatient department without the need for local anesthetic. 
One can sample nodules as small as 1 cm and even smaller if the nodule is 
easily accessible. Skill in the interpretation of FNB specimens is readily 
acquired by qualified cytopathologists after study of reference material and 
the acquisition of reasonable experience. 
The advantages of FNB are summed up in the acronym SAFE: it is Simple, 
Accurate, Fast, Economic, and, indeed, safe. 
FNB is not, however, a substitute for conventional surgical Histopathology. 
Instead, it should be regarded as a component of the pretreatment study of 
pathological processes in combination with clinical, radiological, and other 
laboratory data. 
The fears that led to hesitation about thyroid FNB have not been borne out. 
They included doubt that the number of thyroid operations would be 
reduced, concern that there would be a significant number of thyroid cancers 
missed because of false-negative FNB results, and worry that tumor could be 
seeded along a needle track. Seeding has been described only in two reports 
involving large-needle biopsies and one FNB. 
However, in aspiration of thyroid lesions, an unsatisfactory specimen, 
especially mixed with blood, poses an obstacle in proper cytological 
interpretation.  
In an attempt to overcome the problem of vascularity of the thyroid gland, 
an alternative fine needle sampling method was developed in France. It 
avoids aspiration, utilizes only the needle and relies on capillary pressure to 
suck the cells inside the needle bore. This technique of Fine Needle 
Capillary Sampling (FNC) was termed as Cytopuncture by Brifford 14 in 
1982. 
 
 
 
 
ANATOMY OF THYROID 
 
 Leonardo da vinci originally depicted the thyroid in his drawings as 
two separate glands on either side of the larynx. The term thyroid 
(Greek thyreoeides, shield shaped) was given by Thomas Wharton in his 
Adenographia (1656). 
     The Thyroid Gland (Glandula Thyreiodea; Thyroid Body) is a highly 
vascular organ, situated at the front and sides of the neck; it consists of 
right and left lobes connected across the middle line by a narrow 
portion, the isthmus. It weighs usually about 30 grams.   
     The lobes (lobuli gl. thyreoideæ) are conical in shape, the apex of 
each being directed upward and lateralward as far as the junction of the 
middle with the lower third of the thyroid cartilage; the base looks 
downward, and is on a level with the fifth or sixth tracheal ring. Each 
lobe is about 5 cm. long; its greatest width is about 3 cm., and its 
thickness about 2 cm. The lateral or superficial surface is convex, and 
covered by the skin, the superficial and deep fasciæ, the 
Sternocleidomastoideus, the superior belly of the Omohyoideus, the 
Sternohyoideus and Sternothyreoideus, and beneath the last muscle by 
the pretracheal layer of the deep fascia, which forms a capsule for the 
gland. The deep or medial surface is moulded over the underlying 
structures, viz., the thyroid and cricoid cartilages, the trachea, the 
Constrictor pharyngis inferior and posterior part of the 
Cricothyreoideus, the esophagus (particularly on the left side of the 
neck), the superior and inferior thyroid arteries, and the recurrent 
nerves. The anterior border is thin, and inclines obliquely from above 
downward toward the middle line of the neck, while the posterior 
border is thick and overlaps the common carotid artery, and, as a rule, 
the Parathyroids.  
  The isthmus (isthmus gl. thyreoidea) connects together the lower thirds 
of the lobes; it measures about 1.25 cm. in breadth, and the same in 
depth, and usually covers the second and third rings of the trachea. In 
the middle line of the neck it is covered by the skin and fascia, and close 
to the middle line, on either side, by the Sternothyreoideus. Across its 
upper border runs an anastomotic branch uniting the two superior 
thyroid arteries; at its lower border are the inferior thyroid veins.  
  A third lobe, of conical shape, called the pyramidal lobe, frequently 
arises from the upper part of the isthmus, or from the adjacent portion 
of either lobe, but most commonly the left, and ascends as far as the 
hyoid bone.  
  A fibrous or muscular band is sometimes found attached, above, to the 
body of the hyoid bone, and below to the isthmus of the gland, or 
pyramidal lobe. When muscular, it is termed the Levator glandulæ 
thyreoideæ.  
HISTOLOGY OF THYROID 
 
 
Microscopically, the thyroid gland is made up of round or oval follicles, 
with an average diameter of 200 µm. They are lined by a single layer of 
follicular cells whose shape ranges from flattened to low columnar 
depending on their degree of activity. The cytoplasm has a pale acidophilic 
or amphophilic staining quality; the greater the activity of the cell, the 
greater its amount. Follicular cells with abundant granular acidophilic 
cytoplasm are referred to as Hürthle cells (a misnomer), Askanazy's cells, 
oxyphilic cells, or oncocytes. 
   Ultrastructurally, this granularity is due to the accumulation of 
mitochondria. They can be detected immunohistochemically with antibodies 
directed against mitochondrial enzymes. 
   The main ultrastructural features of follicular cells are abundant granular 
endoplasmic reticulum, a well-developed Golgi apparatus, lysosomes 
(particularly numerous in actively secreting cells, and mainly located toward 
the apical side), and numerous microvilli in the luminal border. The intra-
luminal colloid is pale staining and with scalloped borders in follicles with 
active secretory function and densely eosinophilic in inactive ones. It is  
 
variably PAS positive and alcianophilic, depending on the types and relative 
amounts of carbohydrate components present. Birefringent calcium oxalate 
crystals may be found, their number increasing with age. Collections of 
small follicles protruding into the lumen of larger follicles are commonly 
seen in actively secreting glands; they are sometimes referred to as 
Sanderson's polsters. 
   Immunohistochemically, reactivity for thyroglobulin, triiodothyronine 
(T3), and thyroxine (T4) is found both in the colloid and in the cytoplasm of 
the follicular cells. Thyroglobulin is the most useful of these markers. 
   Neuroendocrine cells of presumed neural crest derivation known as C cells 
or Parafollicular cells represent the other major epithelial component of the 
thyroid gland. The latter term is a misnomer, because immunohistochemical  
and ultrastructural studies have shown that they occupy an exclusively 
intrafollicular position. C cells are restricted to the middle and upper thirds 
of the lateral lobes along their central axes. The number of C cells varies 
according to age; they are more numerous in infancy and old age than in 
adults. 
   Ultrastructurally, C cells contain numerous dense-core granules of 
neurosecretory type. They are argyrophilic with the Grimelius reaction; 
metachromatic with toluidine blue; and positive for lead hematoxylin. 
EVOLUTION OF THYROID CYTOLOGY 
 
For over 100 years the discipline of Pathology was essentially diagnostic 
Histopathology and this in turn on surgical biopsy. For the last 60 years, 
exfoliated and abraded sample of cells have also been collected from 
accessible anatomical surfaces, especially from the uterine cervix and the 
bronchus. Thus a diagnostic discipline has arisen in parallel with 
Histopathology which subserves both a screening and predictive function. 
    In 1883 Leyden et al 10 and 3 years later Menetrier 11 employed needles to 
obtain cells and tissue fragments, the former to isolate pneumonic 
microorganisms and the latter to diagnose pulmonary carcinoma. 
In 1919 Hirshfeldt H et al 12 study revealed the wide acceptance of needling 
the bone marrow an integral part of the investigation of hematological 
problems which continued to serve as a remainder that almost every tissue 
could be sampled by an easily acquired technique requiring neither 
anesthesia nor the  surgical intervention. 
Almost 70 years ago, Fred Stewart, a surgical pathologist at the Memorial 
Hospital Laboratory in New York, published the results of 2,500 tumors 
biopsied by an aspiration method using an 18-gauge needle. Stewart's report 
marked the onset of needle aspiration in the U.S. as a form of biopsy.  
 The concept of FNAC for thyroid swellings was first introduced by Martin 
& Ellis (1930) at the Memorial Sloan – Kettering Hospital, who used an 18-
gauge needle aspiration technique. Subsequently, cutting needle biopsy 
using Silverman or Tru-Cut needles was used for tissue examination. None 
of these techniques gained wide acceptance because of fear of malignant 
implants in the needle track, false-negative results, and serious 
complications. 
 True fine needles for aspiration (22- to 27-gauge vs. 18-gauge) were first 
introduced by Lopez-Cardozo in The Netherlands and Soderström in 
Sweden in the 1950s. At that time, the European clinicians developed the 
use of Romanowsky and May-Grünwald Giemsa stains (similar to Diff-
Quick or Wright's stain for blood smears) for use on air-dried smears to 
allow for rapid interpretation. Despite their success, it was not until the 
1980s that fine-needle aspiration (FNA) biopsy became popular in the U.S. 
In 1981 Ashcraft and van Herle exhaustively reviewed preoperative 
diagnostic techniques for thyroid nodules and concluded that needle biopsy 
was the best of those available, but skepticism was expressed as late as 
1984.Since then, FNB has gained progressively wider acceptance, including 
endorsement by the American Thyroid Association and the American 
Association of Clinical Endocrinologists, and is now in general use because 
its advantages have been confirmed. Currently, this technique is practiced 
worldwide. 
In India, the technique was first introduced at Chandigarh in the early 
seventies followed by AIIMS, New Delhi, in the mid seventies. The first 
major study by an Indian was the one done by Rao S K et al 13, in which 
about 341 cases of solitary thyroid nodules were evaluated over a period of 
10 years. 
The technique of Non Aspiration Cytology for thyroid lesions was first 
evaluated and compared with the conventional FNAC by Santos and Leiman 
(1988) in 50 nodular lesions. 
Since then numerous studies have been conducted and many are still being 
under evaluation to assess the advantages if any of this technique over the 
conventional aspiration technique. 
 
 
 
 
 
CYTOPATHOLOGY 
 
BENIGN NON-NEOPLASTIC LESIONS: 
 
Chronic Lymphocytic Thyroiditis:  
 
Fine needle aspirates from autoimmune (Hashimoto’s) thyroiditis are 
generally moderately cellular, characterized by a mixed population of 
mature and transformed lymphocytes, plasma cells, histiocytes, and 
occasional tingible-body macrophages. This inflammatory component is 
accompanied by aggregates of follicular cells, Hürthle cells, and scant 
colloid. Difficulties can be encountered in distinguishing between 
lymphocytic thyroiditis and Hürthle cell neoplasm. Lymphomas arising in 
the setting of Hashimoto’s thyroiditis are most often large cell type and may 
be recognized in aspirate material by a monotonous population of large 
atypical lymphoid cells. The FNA finding of a predominant and/or atypical 
lymphoid population in the setting of Hashimoto’s thyroiditis should prompt 
immunophenotyping evaluation either by immunocytochemistry or flow 
cytometry. 
  
 
 
Nodular Goiter:  
 
Fine needle aspirations from nodular goiter yield abundant colloid, scant 
to moderate amounts of follicular epithelium, appearing predominantly as 
flat sheets, occasionally accompanied by Hürthle cell change, and a variable 
reactive component consisting of macrophages, fibroconnective tissue and 
inflammatory cells. Aspirates of hyperplastic nodules exhibit a more 
abundant epithelial component that retains bland, uniform morphology and a 
background of abundant colloid. The reactive component predominates in 
aspirates of hemorrhagic cysts, yielding numerous hemosiderin-laden 
macrophages along with abundant colloid. However, it should be noted that 
up to 15% of cystic lesions might represent cystic degeneration of a 
neoplasm, most commonly papillary carcinoma. This highlights the 
importance of repeat sampling of any solid areas remaining after cyst 
drainage, and provides a rationale for surgical removal of large, persistent 
cysts.  
 
 
NEOPLASTIC LESIONS : 
  
Follicular Neoplasm: 
  
Fine needle aspiration specimens from follicular neoplasm’s are cellular 
with scant to absent colloid. The follicular epithelium appears in syncytial 
fragments with microfollicular or trabecular patterns. Both morphologic and 
morphometric studies have emphasized the features of increased nuclear 
size, nuclear pleomorphism, and crowding as helpful in the specific 
cytological diagnosis of follicular carcinoma. However, in routine practice, 
most follicular carcinomas and follicular adenomas have a similar 
cytological pattern. This pattern may be indistinguishable, in 15% to 25% of 
cases, from hyperplastic nodule in goiter. Similarly, overlapping cytological 
criteria occur between follicular neoplasm and follicular variant of papillary 
carcinoma, particularly when the characteristic nuclear changes are focal and 
not adequately sampled, or are poorly visualized in the aspirated material. 
Generous sampling and optimal specimen preparation minimize these 
limitations of FNA in distinguishing among follicular lesions. Overall, the 
incidence of malignancy in nodules with a cytological diagnosis of follicular 
neoplasm ranges from 15% to 22%.  
 
Hürthle Cell Neoplasm: 
  
Hürthle cell neoplasm aspirates are cellular, with scant colloid, and 
contain cells with abundant, granular cytoplasm and central round nuclei that 
often have prominent nucleoli. The cells are loosely cohesive, appearing in 
aggregates, singly, in monolayers, or follicular patterns. Marked nuclear 
atypia, binucleation, and eccentric nuclei may be common in both adenomas 
and carcinomas and cannot be used as indicators of malignancy. Ordinary 
follicular cells are scarce (<10%) and a lymphocytic infiltrate is absent. The 
differential diagnosis includes chronic lymphocytic thyroiditis, medullary 
carcinoma, and, rarely, papillary carcinoma (particularly tall cell, Hürthle 
cell, or Warthin tumor-like variants).  
Papillary Carcinoma: 
 
Fine needle aspirate specimens from papillary carcinomas show a wide 
range of cytological patterns. High cellularity is a common feature, and 
colloid is usually scant. The epithelium may appear as true papillary 
fragments, but more commonly is arranged in multilayered syncytial 
fragments or branched sheets. A predominant follicular pattern can be seen,  
 
particularly in the follicular variant of papillary carcinoma. Nuclear 
enlargement and pleomorphism are present, along with nuclear crowding, 
finely powdery chromatin, nuclear grooves, and sharply defined intranuclear 
cytoplasmic inclusions that gives the appearance of Orphan Annie eyed 
nuclei. The cytoplasm is usually dense and cyanophilic. Strict attention must 
be paid to finding a set of diagnostic criteria, rather than single isolated 
features, to arrive at the proper diagnosis. The features of multinucleated 
giant cells, seen in 55% to 100% of cases, and psamomma bodies, while not 
specific for papillary carcinoma, are helpful associated findings. There is 
little evidence that the various subtypes of papillary carcinoma can be 
reliably distinguished in cytological specimens.  
Medullary Carcinoma: 
 
Fine needle aspirates from medullary carcinoma are generally highly 
cellular, composed of loosely cohesive sheets and nests of cells. 
Occasionally, paucicellular specimens obscured by blood are encountered. 
The tumor cells have abundant, granular cytoplasm that appears ill-defined 
and contains small eosinophilic granules on Romanowsky-stained 
preparations in 5% to 20% of cells. Eccentrically placed, round nuclei impart  
 
 
a plasmacytoid look to the cells in some medullary tumors, while in 
others a more spindled or pleomorphic morphology predominates. The 
nuclear chromatin is coarsely or finely stippled and intranuclear cytoplasmic 
inclusions may be seen. In the minority of aspirates, the epithelial 
component is accompanied by amyloid appearing as amorphous globules or 
irregularly shaped fragments, resembling colloid. Positive 
immunohistochemical staining for calcitonin is highly specific for medullary 
carcinoma; however, sensitivity may be as low as 55% to 60% in cytological 
material.  
Anaplastic Carcinoma: 
  
The cytological pattern of these tumors is highly varied similar to it’s 
histological picture, but marked cellular pleomorphism and anaplasia, 
accompanied by a necrotic, inflammatory background, are the hallmarks.  
Other Malignancies: 
  
The thyroid gland may be a primary site of lymphoma, or secondarily 
involved by systemic disease. 
 
  
Most thyroid gland lymphomas are of the large cell type, and appear 
cytologically as a monotonous population of round cells with scant 
cytoplasm, finely granular chromatin, and prominent nucleoli. Background 
features of cytoplasmic fragmentation (lymphoglandular bodies) and 
karyorrhexis suggest that the abnormal cells are of lymphoid origin, but 
special immunophenotyping studies are used to confirm monoclonality.  
Metastatic tumors to the thyroid gland make up a small proportion of 
thyroid malignancies. Over a 25-year period at the Mayo Clinic 2.6% of 
thyroid malignancies were metastatic tumors from other sites. Lung, kidney, 
breast, and malignant melanoma are reported to be the most common 
primary sites to metastasize to thyroid, followed by isolated cases from a 
wide variety of sites. Yet the majority of thyroid nodules (71%) that develop 
in patients with known prior malignancy are benign; thus, FNA can play a 
particularly important role in these patients. 
  
 
 
FINE NEEDLE BIOPSY 
 
SELECTION OF NEEDLE: 
 
Twenty-five–gauge, 1½-inch needles produce excellent specimens and 
are less likely to cause bleeding that dilutes specimens and thereby greatly 
reduces their usefulness. The ease with which bleeding is induced depends 
not only on needle size but also on the structure of the nodule. Occasionally, 
22- or 23-gauge needles may be best for particularly hard papillary 
carcinomas and other fibrotic nodules. Larger needles (23-gauge) may be 
used to drain cysts, followed by reaspiration of any remaining solid areas 
with a 25-gauge needle. 
 
POSITIONING THE PATIENT: 
 
The patient lies supine, with a pillow under the shoulders to facilitate neck 
extension and is asked not to talk or swallow while the needle is in the neck. 
The skin is cleaned with alcohol. 
 
 
APPROACH: 
The operator stands on the side of the patient opposite to that of the 
thyroid nodule. Current regulations require the use of gloves because of 
concern about blood-borne diseases. The fingers of one hand fix the nodule, 
and the needle in the other hand is inserted perpendicular to the anterior 
surface of the neck. The angle of approach is medial to lateral, placing the 
needle below the strap muscles and in front of the trachea, making short, 
rapid strokes with only slight changes in direction. 
 
SPECIMEN ADEQUACY: 
         Several factors influence non-diagnostic rates for FNB results, 
including the skill of the operator, vascularity of the nodule, criteria used to 
judge adequacy of the specimen, and the cystic component of the nodule. 
Studies have shown average insufficiency rates in the 15% to 20% range.  
The non-diagnostic thyroid aspirate can pose a dilemma in clinical   
management, with cancer rates of 4% to 9% among non-diagnostic thyroid 
FN Biopsies. 
On-site microscopic assessment, with reaspiration when necessary, can 
minimize the number of inadequate specimens. Reaspiration yields 
satisfactory specimens in at least 50% of cases that are considered non-
diagnostic on initial FNB. Although it has been suggested that more 
aspirations will increase the diagnostic rates, the optimal number of 
aspirations is a matter of debate. In general, most reports indicate that two to 
four aspirates per nodule are adequate. 
 While it is generally agreed that the presence of follicular cells is a 
minimum requirement for thyroid cytology adequacy, the absolute number 
of cells is subject to debate. 
 Some authors propose adequacy criteria of five to six groups of well-
preserved follicular cells, with each group containing ten or more cells. 
Others require eight to ten fragments of well-preserved follicular cells on at 
least two smears. 
To increase chances of adequate cellular material, at least six separate 
specimens that appear grossly satisfactory are necessary. Preferably, the 
aspirates should be obtained from the peripheral areas and different parts of 
the nodule, in a sequential manner, to ensure representative sampling. For 
larger nodules, the deep center of the mass should be avoided because it is 
more likely to contain degeneration and fluid, decreasing the chance of a 
diagnostic specimen. For cystic lesions, the fluid should be completely 
aspirated and FNA attempted on residual tissue. 
 
FINE NEEDLE ASPIRATION CYTOLOGY (FNAC): 
 
A 10-mL syringe is used, the plunger is withdrawn about two thirds of the 
way to produce negative pressure, and one looks for fluid in the needle hub. 
At the first appearance of fluid, negative pressure is released and the needle 
withdrawn. No fluid should enter the syringe. If this happens, the specimen 
will be too dilute and may be lost in the syringe. 
Material may appear in the syringe if too large a needle is used, if negative 
pressure is too vigorous, if the nodule is extensively degenerated or 
unusually vascular, or if the nodule is cystic. For the first two possibilities, 
adjustments can be made to improve the chances for success with 
subsequent punctures. The last two situations are beyond control, although it 
may help to insert the needle at the nodule periphery, where degeneration is 
less likely. 
The initial aspiration may produce no specimen if the needle is not in the 
nodule, if the needle is too fine, if negative pressure is not vigorous enough, 
or if the nodule is fibrotic. If negative pressure fails to produce fluid, the 
simplest method to disrupt the tissue is to move the needle in and out within 
the nodule through a vertical distance of 1 to 2 mm. This maneuver nearly 
always yields a specimen, but if not, one can combine in-and-out movement 
with rotation of the needle, to sever small tissue fragments. If the nodule is 
purely cystic, it will collapse with aspiration. If there is a solid component, 
FNB samples should be taken from any residual mass. Examining the 
sediment from cyst fluid rarely yields useful information. 
 
 FINE NEEDLE NON ASPIRATION CYTOLOGY (FNNAC): 
 
  It relies on the property of capillary tension in narrow channels. This 
physical principle states that a fluid (or semi fluid substance) will ascend 
spontaneously into a narrow tube in inverse proportion to the diameter of 
that tube. The needle is held in a pencil grip, which facilitates precise needle 
placement for small nodules, and allows the needle to be moved both in and 
out over a few millimeters and rotated. This combined motion uses the bevel 
of the needle for cutting, which frees cells that flow into the needle by 
capillary action while the needle is held steady for about 10 seconds. 
Material entering the hub of the needle is readily visible. 
 
 
SMEAR  PREPARATION  : 
 
Slides are labeled and placed on the table before aspiration, ready for use. 
Five milliliters of air is aspirated into the syringe, and the needle placed on 
the syringe. With needle bevel pointing down, one drop of aspirated material 
is expelled onto each of several glass slides A grossly satisfactory FNB 
specimen consists of a small amount of red-orange fluid. Smears are 
prepared in a manner similar to that for blood smears, in which a second 
slide is held at a 45- to 60-degree angle to the specimen on an underlying 
slide. The specimen is allowed to spread out along the edge of the upper 
slide, which is then advanced along the lower slide, drawing the  specimen 
into a smear. This method may produce thick, uneven smears. 
The following alternative maneuver produces flat, uniformly dispersed 
smears: a top slide is placed flat on the bottom, specimen slide, and, with the 
index finger, the top slide is pressed down onto the specimen and drawn 
over the bottom slide. 
Slides are then immediately wet-fixed by placing them in alcohol bottle. Air-
dried smears are often prepared with a Romanovsky stain. Some pathologists 
use air-dried smears stained with a modified Romanovsky stain called May-
Giemsa-Grünwald (MGG) stain, which enhances cytoplasmic detail, but 
most American cytopathologists prefer the crisp nuclear detail obtained with 
the Papanicolaou stain, which needs immediate fixation, before air drying 
takes place. In some centers FNB specimens are expelled from the needle 
directly into a fixative/preservative solution, and slides are later prepared in 
the laboratory. This permits the use of methods that concentrate the thyroid 
cells and eliminate red blood cells. 
 
POST PROCEDURE OBSERVATION: 
After the biopsy has been completed, firm pressure is applied to biopsy 
site(s) with gauze pad. Once bleeding has stopped, an adhesive bandage 
(Band-Aid) is placed on the puncture site(s) and the patient is observed for a 
few minutes and, if there are no problems, allowed to leave. 
 
OTHER USES OF THYROID FNB: 
 
If the rare entity of acute suppurative thyroiditis is suspected, FNB can 
provide material for Gram stain and culture. 
Special stains have identified Pneumocystis carinii as the cause of both 
painful and painless thyroid enlargement in patients with the acquired 
immune deficiency syndrome.  
One research study described a mutation in the thyroid-stimulating hormone 
receptor gene in autonomously functioning thyroid adenomas, using RNA 
obtained by FNB as a template for complementary DNA synthesis, followed 
by polymerase chain reaction amplification. 
ANCILLARY STUDIES:  
                      Effective criteria for the cytologic diagnosis of thyroid 
lesions are well established, yet areas of diagnostic uncertainty remain. This 
has led to a search for useful markers of thyroid malignancy that can be 
applied to cytologic specimens. Studies of vimentin, lectins, and different 
molecular weight cytokeratins as indicators of thyroid malignancy have met 
with only limited success, particularly in cytologic material. More promising 
results were reported in studies describing the immunodetection of the 
enzyme thyroperoxidase (TPO) in fine needle aspirates of thyroid 
malignancies. CD44, lactoferrin, and HBME-1 are other markers with 
specificity for thyroid malignancies in preliminary studies. 
SEQUELAE OF THYROID FNB:  
 
A range of tissue effects has been described in thyroid resections 
following FNB. The observed tissue alterations are grouped into acute 
(within 3 weeks of FNB) and chronic categories. 
 The acute changes include hemorrhage, granulation tissue, giant cells, 
hemosiderin-laden macrophages, necrosis, and, rarely, infarction 16. Among 
the chronic changes are various types of metaplasia (oncocytic, spindle cell, 
and squamous), linear fibrosis, infarction, pseudo-invasion of the capsule, 
random nuclear atypia, and papillary degeneration.  
In a comprehensive review of 3,000 thyroidectomies, LiVolsi and 
Merino15 observed post–fine needle biopsy changes in 300 cases. Others 
have reported similar rates of tissue damage. These reports highlight the 
critical importance of providing information on prior fine needle aspiration 
procedure and the cytological diagnosis to the pathologist handling 
subsequent tissue samples of a thyroid nodule. 
 
LIMITATIONS OF THYROID NEEDLE BIOPSY: 
The principal limitation is inexperience, both in obtaining adequate 
specimens and in interpreting the specimens. 
 FNB is not applicable to all nodules. Some are too small and too 
inaccessible for accurate needle placement, or too far down in the chest to be 
aspirated safely. Others are so degenerated that useful material cannot be 
obtained. 
Several authors have discussed the problem of follicular neoplasm. Kini  
believes that follicular adenomas and follicular carcinomas usually can be 
differentiated on the basis of nuclear size but Hürthle cell lesions are 
problematic to diagnose cytologically. Other pathologists maintain that 
benign and malignant follicular/Hürthle cell tumors cannot be distinguished 
on the basis of aspirated cells only as it requires the demonstration of 
vascular or capsular invasion and the lesion must be removed for 
histopathologic examination. 
 Recent studies suggest that immunohistochemical and genetic markers may 
be useful in improving diagnostic accuracy in this group. Two such markers, 
HBME-1 and galectin-3, have shown most promise. 
Hypercellular specimens from follicular or Hürthle cell lesions may have 
features suggestive of, but not diagnostic for, malignancy. Thus, the 
cytopathologist labels these "suspicious for malignancy" because cytological 
features neither confirm nor rule out malignancy. Histological examination 
is necessary for definitive diagnosis. 
Finally, FNB diagnosis of benign for one nodule says nothing about other 
nodules, whether palpable or impalpable. 
 
POTENTIAL COMPLICATIONS OF NEEDLE BIOPSY: 
 
Occasionally, there is a local hematoma after FNB. An ice pack is adequate 
treatment. Rarely, the entire thyroid gland swells acutely; this spontaneously 
resolves within 24 to 48 hours or less. The use of anticoagulants or 
salicylates does not preclude FN Biopsy.  
Seeding a malignancy in the needle track has been reported very rarely after 
large needle biopsies but had no unfavorable impact on prognosis.  
Although FNB, like an ordinary venipuncture, is a clean rather than strictly 
sterile procedure, infection has not been reported with thyroid FNB. 
 If the needle enters the trachea, which occasionally happens when a 
medially situated nodule is sampled, the specimen consists of mucus and air, 
and the patient may cough, but no harm is done.  
If a serum thyroglobulin measurement is desired, it should be done on blood 
drawn either before or at least 10 to 14 days after thyroid FNB because the 
serum thyroglobulin concentration can increase substantially after FNB. 
The social and legal consequences of false-positive or false-negative 
diagnoses are of concern. 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
¾ To assess the efficacy and accuracy of fine needle aspiration cytology  
          and non aspiration cytology in evaluation of thyroid malignancies in   
          correlation with histological diagnosis. 
 
¾ To compare the two techniques with regard to diagnostic yield and 
          quality of smear obtained ,especially with regard to malignant smears.     
  
 
 
 
 
MATERIALS AND METHODS 
 
The study was undertaken in the Department of General Surgery and the 
Department of Pathology, Madurai Medical College, Madurai, Tamil Nadu, 
India for a period of 25 months, from June 2004 to June 2006.  
The design of the study was cross sectional diagnostic test evaluation. 
All patients with thyroid swellings treated by the surgical units of 
Government Rajaji Hospital either as outpatients or inpatients during the 
above study period were randomly divided into two groups. 
For one group, cytology smear was obtained by aspiration technique, and for 
the other group the smears were obtained by non-aspiration technique. The 
relevant clinical details of these patients were also obtained for the purpose 
of the study. 
25 gauge, 1-½ inch needles were used for obtaining smears by both 
Aspiration and Non aspiration techniques (10 ml syringes were used for 
aspiration technique). Smears were fixed in 95% alcohol for Papanicolaou 
and Haematoxylin & Eosin staining. 
All the smears were obtained by a single observer. The smears were reported 
by cytopathologist, blinded to the technique employed. 
 
All the smears in both the category, which had the corresponding 
postoperative Histopathological diagnosis, were included for the study 
purpose. This amounted to 141 smears in the Aspiration group and 148 
smears in the Non aspiration group. 
 For histological examination, specimens were fixed in formalin. After 
paraffin embedding, 5-micron thick sections were made and attained with H 
& E and PAP stains. Special stains were used as and when required (Congo 
red for demonstration of amyloid in cases of medullary carcinoma).  
The cytology smears were classified into one of the five categories for 
diagnostic purpose by the cytopathologist. In addition the smears were 
classified into one of the three categories described below with regards to 
the quality of smear by the cytopathologist. 
The cytology diagnosis were tabulated with respect to the corresponding 
postoperative Histopathological diagnosis in both categories and the efficacy 
of cytology smear interpretation in relevance to diagnosis of thyroid 
swellings in particular the malignancies were evaluated by specific 
parameters namely sensitivity, specificity, accuracy, percentage of false 
negatives & false positives. 
SMEAR CLASSIFICATION 
 
PATHOLOGICAL CLASSIFICATION: 
 
THY I    : Inadequate / unsatisfactory / non diagnostic 
               
THY II   : Non neoplastic and benign thyroid lesions 
 
THY III  : Follicular neoplasms 
 
THY IV  : Suspicious of malignancy 
 
THY V   : Diagnostic of malignancy 
 
QUALITATIVE CLASSIFICATION: 
 
Unsuitable specimens(UNS): consisted mainly of red blood cells or absent  
cellularity making them inadequate for cytodiagnosis. 
Diagnostically adequate(DA): possible to render an opinion on the nature 
of the lesion sampled, but the cellular material present was sub-optimal due 
to poor cellularity, sample dilution, degenerative changes or specimen 
entrapment in blood clots. 
Diagnostically superior(DS): Cell aggregates were prominent, well-
preserved, unobscured by  blood and cell morphology was well displayed. 
               EVALUATION OF CYTOLOGY 
The efficacy of cytology study as a diagnostic / screening tool for thyroid 
malignancy is evaluated by calculation of the following parameters:  
HPE REPORT  
 
CYTOLOGY REPORT 
MALIGNANT NON 
MALIGNANT 
 
POSITIVE a(true 
positive) 
b(false 
positive) 
a + b 
NEGATIVE c(false 
negative) 
d(true 
negative) 
c + d 
 a + c b + d a+b+c+d 
 
Sensitivity = a / (a+c) x 100 
 
Specificity = d / (b+d) x 100 
 
Accuracy = a + d / (a+b+c+d) x 100 
 
Percentage of false negatives = c / (a+c) x 100 
 
Percentage of false positives = b / (b+d) x 100  
OBSERVATION 
 
¾ Total number of cases studied = 289   
 
 
AGE INCIDENCE:  
 
AGE BENIGN MALIGNANT TOTAL CASES 
< / = 20 YRS 24 - 24 (8.3 %) 
21 – 30 YRS 86 14 100 (34.6 %) 
31 – 40 YRS 40 45 85 (29.4 %) 
41 – 50 YRS 12 34 46 (15.9 %) 
51 – 60 YRS 7 18 25 (8.7 %) 
> 60 YRS 1 8 9 (3.1 %) 
TOTAL 170 119 289 
                                                                                           
 
 
SEX INCIDENCE: 
 
 BENIGN MALIGNANT TOTAL 
MALES 11 23 34 (12 %) 
FEMALES 159 96 255 (88 %) 
TOTAL 170 119 289 
 
 HISTOLOGICAL DIAGNOSIS: 
 
 
HPE DIAGNOSIS NO. OF CASES TOTAL 
FOLLICULAR ADENOMA 123 (42.6 %) 
MULTINODULAR 
GOITRE 
31(10.7 %) 
HASHIMATO’S 
THYROIDITIS 
16(5.5 %) 
 
BENIGN 
 
170(58.8 %) 
PAPILLARY 
CARCINOMA 
83(28.8 %) 
FOLLICULAR 
CARCINOMA 
24(8.4 %) 
MEDULLARY 
CARCINOMA 
5(1.7 %) 
ANAPLASTIC 
CARCINOMA 
3(1 %) 
 
 
 
 
 
MALIGNANT 
 
POORLY 
DIFFERENTIATED 
CARCINOMA 
3(1 %) 
SPINDLE CELL 
SARCOMA 
1(0.3 %) 
119(41. 2 %) 
 
 
 
 
SMEAR & HPE REPORT ANALYSIS 
 
ASPIRATION CYTOLOGY (n =141) : 
 
CYTOLOGY DIAGNOSIS:                   SMEAR QUALIFICATION: 
 
 
 
                                  
                                      
   
 
 
HISTOLOGY DIAGNOSIS: 
 
Follicular adenoma                                --- 6 4 (45.39%) 
THY I 20 14.18% 
THY II 16 11.37% 
THY III 51 36.17% 
THY IV 14 9.92% 
THY V 40 28.36% 
 
UNS 20 14.18% 
DA 98 69.56% 
DS 23 16.26% 
Non-neoplastic                                       --- 21 (14.89%) 
        MNG                                                  -- 12  
        Hashimato’s thyroiditis                      -- 9  
Papillary carcinoma                               --- 40 (45.39%) 
Follicular arcinoma                                --- 11 (7.8%) 
Medullary carcinoma                             --- 2 (1.42%) 
Anaplastic carcinoma                             --- 1 (0.71%) 
Poorly differentiated carcinoma             --- 1 (0.71%) 
Spindle cell sarcoma                               --- 1 (0.71%) 
 
SMEAR & HPE REPORT ANALYSIS 
 
NON ASPIRATION CYTOLOGY (n =148) : 
 
CYTOLOGY DIAGNOSIS:                   SMEAR QUALIFICATION: 
 
 
 
 
 
 
 
 
 
HISTOLOGY DIAGNOSIS: 
THY I 3 2.02% 
THY II 23 15.54% 
THY III 61 41.22% 
THY IV 15 10.14% 
THY V 46 31.08% 
 
UNS 3 2.02% 
DA 79 53.37% 
DS 66 44.59% 
 
Follicular adenoma                               --- 59 (39.86%) 
Non-neoplastic                                      --- 26 (17.57%) 
        MNG                                                  -- 19  
        Hashimato’s thyroiditis                      -- 7  
Papillary carcinoma                              --- 43 (29.05%) 
Follicular carcinoma                              --- 13 (8.78%) 
Medullary carcinoma                            --- 3 (2.02%) 
Anaplastic carcinoma                            --- 2 (1.35%) 
Poorly differentiated carcinoma            --- 2 (1.35%) 
 SMEAR QUALITATIVE ANALYSIS 
 
 
ASPIRATION CYTOLOGY: 
 
 
CYTOLOGY REPORT  
 
SMEAR QUALITY 
MALIGNANT 
(n=40) 
NON 
MALIGNANT 
(n=81) 
TOTAL 
DIAGNOSTICALLY 
ADEQUATE  
33 (82.5%) 65 (80.25%) 98 
DIAGNOSTICALLY 
SUPERIOR  
7 (17.5%) 16 (19.75%) 23 
TOTAL 40 81 121 
 
 
 
 
 
SMEAR QUALITATIVE ANALYSIS 
 
 
 
NON ASPIRATION CYTOLOGY: 
 
 
CYTOLOGY REPORT  
 
SMEAR QUALITY 
MALIGNANT 
(n=46) 
NON 
MALIGNANT 
(n=99) 
TOTAL 
DIAGNOSTICALLY 
ADEQUATE  
27 (58.7%) 52 (52.53%) 79 
DIAGNOSTICALLY 
SUPERIOR  
19 (41.3%) 47 (47.47%) 66 
TOTAL 46 99 145 
 
 
 
 
CYTOLOGY & HPE CORRELATION 
 
 
ASPIRATION CYTOLOGY:(n =141) 
 
 
 
 
 
CYTOLOGY & HPE CORRELATION 
 
 
 
NON ASPIRATION CYTOLOGY:(n =148) 
HPE DIAGNOSIS  
 
SMEAR 
CATEGORY 
 
 
NO. OF 
SMEARS 
HASHI MNG FOLL. 
ADENO 
PAP. 
CA 
FOLL. 
CA 
MED. 
CA 
ANA. 
CA 
POOLY 
DIFF. 
CA 
 
SPINDLE 
CELL 
SAR. 
THY I 20 - - 18 1 - - - - 1 
THY II 16 5 8 2 1 - - - - - 
THY III 51 1 1 44 - 5 - - - - 
THY IV 14 2 3 - - 6 2 - 1 - 
THY V 40 1 - - 38 - - 1 - - 
TOTAL 141 9 12 64 40 11 2 1 1 1 
  
 
 
 
 EFFICACY OF CYTOLOGY IN 
DIAGNOSIS OF MALIGNANCY 
 
ASPIRATION CYTOLOGY : 
 
HPE DIAGNOSIS  
 
SMEAR 
CATEGORY 
 
 
NO. OF 
SMEARS 
HASHI MNG FOLL. 
ADENO 
PAP. 
CA 
FOLL. 
CA 
MED. 
CA 
ANA. 
CA 
POOLY 
DIFF. 
CA 
 
THY I 3 - 1 1 1 - - - - 
THY II 23 5 14 3 1 - - - - 
THY III 61 - - 55 - 6 - - - 
THY IV 15 1 3 - 1 7 2 - 1 
THY V 46 1 1 - 40 - 1 2 1 
TOTAL 148 7 19 59 43 13 3 2 2 
HPE REPORT  
 
CYTOLOGY REPORT 
MALIGNANT NON 
MALIGNANT 
 
TOTAL 
POSITIVE 39 1 40 
NEGATIVE 1 15 16 
TOTAL 40 16 56 
 
SENSITIVITY                            = 97.5 % 
 
SPECIFICITY                           = 93.75 % 
 
ACCURACY                             = 96.43 % 
 
% OF FALSE NEGATIVES      = 2.5 % 
 
% OF FALSE POSITIVES       = 6.25 % 
 
EFFICACY OF CYTOLOGY IN 
DIAGNOSIS OF MALIGNANCY 
 
NON ASPIRATION CYTOLOGY : 
 
HPE REPORT  
 
CYTOLOGY REPORT 
MALIGNANT NON 
MALIGNANT 
 
TOTAL 
POSITIVE 44 2 46 
NEGATIVE 1 22 23 
TOTAL 45 24 69 
 
SENSITIVITY                            = 97.77 % 
 
SPECIFICITY                           = 91.66 % 
 
ACCURACY                             = 95.65 % 
 
% OF FALSE NEGATIVES      = 2.22 % 
 
% OF FALSE POSITIVES       = 8.33 % 
 
SUMMARY 
 
1) Total number of cases studied – 289 
2) 58.8 % of the cases were benign lesions, whereas malignancies accounted 
for 41.2 % of the cases. 
3) Most common histological diagnosis was Follicular adenoma (42.6 %). 
4) Papillary carcinoma (28.8 % of all cases) was the most common among 
the malignancies. 
5) Male to Female ratio – 1: 7.5, females constituted 88 % of total cases; the 
male to female ratio for malignancies was 1: 4.  
6) Malignancies account for 68 % of histological diagnosis in males and 38 
% in females. 
7) Overall thyroid swellings were more common in the 21 to 30 years age 
group. 
8) Benign lesions were more common in the age group of 21 to 30 years, 
whereas Malignancies were more common in the age group of 31 to 40 
years. 
9) Sensitivity & Specificity of FNAC were 97.5 % and 93.75 % whereas 
those for FNNAC were 97.77 % and 91.66 % respectively. 
 
 
10) Overall the Diagnostic Accuracy of FNAC and FNNAC for malignancy 
of thyroid were observed as 96.43% & 95.65% respectively. 
11) For both benign and malignant smears, more number of diagnostically 
superior smears were obtained with Non aspiration technique (44.59 % 
overall) when compared to Aspiration technique (16.26 %).  
12) Among the malignant smears 17.5% were Diagnostically Superior in the 
Aspiration group whereas the same for Non-aspiration group was 41.3%. 
13) The Inadequate smears constituted 14.18% & 2.02% of the total number 
of smears respectively for Aspiration and Non-aspiration techniques.  
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
 
AGE DISTRIBUTION: 
Case Processing Summary
289 100.0% 0 .0% 289 100.0%AGE  * VAR00001
N Percent N Percent N Percent
Included Excluded Total
Cases
 
Report
AGE
35.67 141 12.34 35.00 14 70 56
35.93 148 12.19 35.00 18 70 52
35.81 289 12.24 35.00 14 70 56
VAR00001
FNAC
FNNAC
Total
Mean N Std. Deviation Median Minimum Maximum Range
 
p =0.858- not significant 
SEX DISTRIBUTION: 
Case Processing Summary
289 100.0% 0 .0% 289 100.0%SEX * VAR00001
N Percent N Percent N Percent
Valid Missing Total
Cases
 
SEX * VAR00001 Crosstabulation
Count
125 130 255
16 18 34
141 148 289
F
M
SEX
Total
FNAC FNNAC
VAR00001
Total
  
p = 0.488 – not significant  
 
SMEAR CATEGORY: 
 
Case Processing Summary
289 100.0% 0 .0% 289 100.0%
SMEAR CATEGO
* VAR00001
N Percent N Percent N Percent
Valid Missing Total
Cases
 
 
 
SMEAR CATEGORY * VAR00001 Crosstabulation
Count
20 3 23
16 23 39
51 61 112
14 15 29
40 46 86
141 148 289
THY I
THY II
THY III
THY IV
THY V
SMEAR
CATEGORY
Total
FNAC FNNAC
VAR00001
Total
 
 
p = 0.005 significant 
 
 
More FNAC smears turned out to be THY I Category. 
Difference was statistically significant. 
 
SMEAR QUALITY: 
 
 
Case Processing Summary
289 100.0% 0 .0% 289 100.0%
SMEAR QUALIT
* VAR00001
N Percent N Percent N Percent
Valid Missing Total
Cases
 
 
 
 
SMEAR QUALITY * VAR00001 Crosstabulation
Count
98 79 177
23 66 89
20 3 23
141 148 289
DA
DS
UNS
SMEAR
QUALITY
Total
FNAC FNNAC
VAR00001
Total
 
 
 
 
p<0.001 significant 
 
More FNAC smears were of UNS Category. 
 
Difference was statistically significant. 
 
 
 
 
REVIEW OF LITERATURE  
 
In our study of 289 cases, the sex incidence and age specific incidences 
conform to the epidemiological data given in the literature. Among the 
histological diagnosis, malignancy accounted for about 41 % of the cases. 
This proportionately large number of malignant histologies observed may be 
attributed to the fact that the study was conducted not in community but in a 
tertiary center, where more malignant and suspicious of malignant lesions 
were referred from peripheral and secondary level health care. 
False-Negative Diagnoses: 
 
False-negative results mean missed malignancy. The false-negative rate is 
defined as the percentage of patients with "benign" cytology in whom 
malignant lesions are later confirmed on thyroidectomy. False-negative rates 
generally vary from 1.5% to 11.5% (average, <5%). The frequency of false-
negative cytological diagnosis depends on the number of patients who 
subsequently have surgery and histological review. In most retrospective 
series, less than 10% of patients with a benign cytological diagnosis 
subsequently have thyroid surgery, suggesting that false-negative rates 
should be interpreted with some scepticism. Despite this note of caution, 
most authorities agree that the true false-negative rate is less than 5% if all  
patients have thyroid surgery. The incidence of false negatives observed 
with two techniques Aspiration and Nonaspiration (2.5% & 2.22% 
respectively) in our study was in the range conforming to the standards 
given in the literature.  
False-Positive Diagnoses: 
  
A false-positive diagnosis indicates that a patient with "malignant" FNA 
results was found on histological examination to have benign lesions. False-
positive rates vary from 0 to 8% (average, 3%). The false positivity observed 
in our study were 6.25% & 8.33% respectively for Aspiration and Non-
aspiration techniques that were relatively high when compared to the 
literature.  
Causes of False Diagnoses: 
  
Interpretive or sampling errors account for false diagnoses. Hashimoto's 
thyroiditis probably is the most common cause of false-positive cytology. 
Misclassification of follicular and Hürthle cell adenomas as papillary 
carcinomas accounts for other errors. FN Biopsy of thyroid lymphomas may 
produce lymphocytes that can be interpreted as Hashimoto's thyroiditis, 
accounting for a false-negative diagnosis. 
 Inadequate or improper sampling accounts for some false-negative errors. 
For example, nodules smaller than 1 cm in size may be too small for 
accurate needle placement, and nodules larger than 4 cm in diameter are too 
large to allow proper sampling from all areas, thereby increasing the 
likelihood of misdiagnosis. 
 Review of the literature reveals that the sensitivity of FNA ranges from 65% 
to 98% (mean, 83%), and specificity ranges from 72% to 100% (mean, 
92%). The predictive value of a positive or suspicious cytological result is 
approximately 50%. The overall accuracy for cytological diagnosis 
approaches 95%. The sensitivity and specificity of FNAC in our study was 
97.5 % & 93.75 % respectively. 
In a review by Gharib and Goellner 17,18 of 18,183 FNA biopsies from 
seven large series, sensitivity rates of thyroid FNA range from 65% to 98% 
(mean, 83%) and specificity from 72% to 100% (mean 92%). 
In a review of 2,595 thyroid aspirates from 11 series in which all patients 
underwent surgery, Molitch 19 et al reported a false-negative rate of 2%, a 
5.4% false-positive rate, and a 22% malignancy rate in the group diagnosed 
as follicular neoplasm or suggestive of neoplasm. 
Study conducted by Seyed Mohammad Tavangar et al 20 in 200 patients 
concluded that there was no statistically significant difference between 
FNNA and FNA average scores in each parameter, as noted in our study.  
The non-aspiration technique in 36 benign lesions and 13 neoplasms in a 
study conducted by Santos JE et al 21 obtained diagnostically superior 
specimens significantly more frequently, similar to the results obtained in 
our study. 
Study conducted by Kamal MM et al 22 concluded that although FNC 
sampling was diagnostic in a greater number of cases than FNA sampling, 
there was no proof of clear superiority of FNC over FNA. Until greater 
experience shows clear sampling superiority of FNC alone, rather than 
performing only FNA in diffuse or nodular thyroid lesions, incorporating 
FNC into the second puncture will definitely improve the quality and 
quantity of material at the patient's first visit. The same conclusion was 
derived in our study also.  
Diagnostically superior specimens were obtained significantly more 
frequently by the non-aspiration technique as concluded by Rizvi S A et al 23 
in a study of 150 patients. 
Implementation and adherence to of specific protocols such as an immediate 
FNA interpretation service, standardizing FNA diagnostic terminology, 
based on error reduction initiatives would result in improvement of 
specimen quality and fewer diagnostic errors, as shown by Stephen S.R. 34.  
DISCUSSION 
 
   The thyroid gland was selected for the study of Non-aspiration technique, 
as it is a vascular organ that frequently produces heavily blood stained 
aspirates. Furthermore, many diagnostic pitfalls exist in the interpretation of 
thyroid specimens, making excellence of cellular material a prerequisite for 
diagnosis. 
 
             In our study age and sex distribution was statistically analyzed 
between the two groups and was found to be equally distributed between the 
two. There was no statistically significant variation in the age and sex 
distribution between the two populations. (p values for age & sex 
distribution were 0.858 & 0.488 respectively between the two populations). 
  
            In our study, it was observed that the non-aspiration technique 
yielded more diagnostically superior specimens, as compared with FNA. 
The number of unsuitable smears was also greater in aspiration samples, as 
compared with the non-aspiration technique. The difference was statistically 
significant (p = 0.005).    
       In our study, no significant difference between the performances of 
these two techniques was noted, with respect to making a cytological 
diagnosis of thyroid swellings.  
          Although the presence of blood cannot be entirely prevented in 
thyroid cytology samples, its effect on smear quality is minimized by the 
spontaneous capillary action of the non-aspiration technique as opposed to 
the active, often high suction pressures of conventional FNA procedures. 
The cellular material is more concentrated, less traumatized and less 
obscured by blood or distorted within blood clots in the non-aspiration 
smears. It also offers many other advantages. Fewer patients complain of 
pain or discomfort. The technique is simple, easy to perform and enables an 
enhanced appreciation of the consistency of the mass being sampled. No 
complications were encountered in any of the patients sampled by the non-
aspiration technique. The only disadvantage being acellularity, was noticed 
in three patients in our study. 
Thus the diagnostic accuracy of thyroid cytology in interpretation of 
malignancy primarily depends on various other factors irrespective of the 
technique employed being Aspiration or Non-aspiration. 
 FN CYTOLOGY GUIDELINES 
 
 
 
         Hossein Gharib et al 18 has proposed the following guidelines 
that improve accuracy of Fine-Needle Biopsy (FNB):  
 
1) Individuals who have had training in both thyroid examination and 
thyroid biopsy, such as Endocrinologists, should perform FNB. In the 
hands of experienced operators FNB achieves high diagnostic 
accuracy. 
2)  Aspirates should be obtained from different portions of the nodule, 
preferably peripheral areas, in an organized and sequential manner. It 
is essential to ensure that an adequate number of follicular cells is 
present. 
3) Particular care to be taken with small (< 1 cm) or large (> 4 cm) 
nodules because of increased chance of misdiagnosis. USG-guided 
FNB improves accuracy in this regard.  
4) A cytopathologist, preferably one with experience in thyroid 
cytology, should review and interpret the slides. 
5) Non-diagnostic cytology is not negative because as much as 5%-10% 
of non-diagnostic nodules harbour malignancy. 
6) Repeat Biopsy is mandatory if cytology is non-diagnostic, because 
one-half of previous non diagnostic lesions will be diagnostic on 
reaspiration 
7)  If reaspiration yields insufficient material, US-guided FNB is the 
next test. In the event that the final result is still insufficient, surgical 
excision is warranted for most nodules. 
8) Nodules yielding ”suspicious" cytology should be recommended for 
excision as there is 10%-30% chance of malignancy 
9) Any clinically suspicious, cytologically benign nodule should be 
recommended for excision and cytology is considered false-negative 
until proved otherwise in these lesions 
              In a recent review of thyroid FNA, Belfiore and La Rosa 
suggested     the following steps to reduce false-negative results:  
• Acquire and maintain adequate biopsy expertise  
• Avoid making a diagnosis with a sub optimal sample  
• Be cautious with cystic degeneration, Hurthle cells, or lymphocytes  
• Repeat FNA at least once during follow-up. 
CONCLUSION 
 
Although no significant difference was seen in the efficacy and diagnostic 
accuracy of the two techniques in evaluation of thyroid swellings, the non 
aspiration technique has got it’s own merits. 
 
The non-aspiration technique is simple, easy to perform and produces better 
results in the form of a better quality of the cellularity and less field 
obscurity by blood in both neoplastic and non-neoplastic lesions of the 
thyroid. It has statistically significant less chances of producing non-
diagnostic smears. The technique is free of complications and very much 
comfortable to the patient.  
 
Hence, this technique should be used alone or in tandem with FNAC for  
better diagnostic yield. 
 
Adhering to a set of guidelines would serve to improve the accuracy of 
cytodiagnosis irrespective of the technique and enable better evaluation and 
management of thyroid swellings. 
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ogical features in common Thyroid Lesions 
OGICAL 
NOSIS 
 
COLLOID 
 
CEEL 
ARRANGEMENT 
 
NUCLEUS 
 
CYTOPLASM 
 
MISCELLAN
LAR 
TRE 
 
Scant to abundant groups, 
microfollicles 
 
Monolayers 
 
Pyknotic  
 
Ill defined 
commonly 
 
Cystic change
ONIC 
IDITIS 
 
Absent 
 
Isolated, clusters 
Hyperplastic changes 
 
Degenerative 
 
Degenerative 
&/or hyperplastic 
changes 
 
OMA 
 
Absent to scanty 
 
Microfollicles  
Clusters 
 
Enlarged, with overlapping nucleoli 
 
Scanty 
 
Cystic change
ULAR 
NOMA 
 
Usually absent 
 
Microfollicles 
Clusters  
 
Enlarged, anisinucleosis, atypical, 
overlapping nucleoli 
 
Scanty 
 
LARY 
NOMA 
 
Scanty or absent 
 
Monolayers, papillae 
Microfollicles  
 
Enlarged, grooves, ground glass type, 
inclusions 
 
Ill defined to 
abundant 
 
Psammomas, g
LARY 
NOMA 
 
Absent 
 
Isolated, small clusters 
 
Eccentric, round or elongated, 
hyperchromatic 
 
Polygonal, 
spindle shaped 
azurophillic 
granules 
 
Amyloid  
ASTIC 
NOMA 
 
Absent 
 
Isolated, clusters 
 
Giant or spindle shaped, atypical, large 
nucleoli, 
 
Pleomorphic 
 
Necrosis  
E CELL 
ON 
 
Absent  
 
Isolated, microfollicles 
 
Vesicular, anisonucleosis, prominent 
nucleoli 
Large, 
pleomorphic, 
metachromatic 
granules 
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S.NO. NAME AGE SEX I.P.NO. SMEAR CATEGORY HPE DIAGNOSIS
1 DEVAMANOHARI 42 F 222964 THY V PAP CA
2 KRISHNAVENI 28 F 399406 THYII MNG
3 KALYANI 42 F 392153 THY II FOLL.ADENO.
4 VIJAYA 40 F 396962 THY I FOLL.ADENO.
5 LAKSHMI 38 F 208813 THY V PAP CA
6 AMUDHA 23 F 206747 THY II HASHIMATO'S
7 MUTHAMMAL 26 F 205090 THY III FOLL.ADENO.
8 PADMA 30 F 375813 THY III FOLL.ADENO.
9 KOOTHAR 59 M 291704 THY IV FOLL.CA.
10 MOHANAVALLI 45 F 396388 THY V PAP CA
11 SUMATHY 22 F 395960 THY I FOLL.ADENO.
12 SUMATHY 35 F 394695 THY II MNG
13 PARVATHY 21 F 396074 THY II MNG
14 KANTHIMATHI 39 F 395522 THY I FOLL.ADENO.
15 NIRMALA 27 F 393465 THY V PAP CA
16 SHANTHI 26 F 194269 THYIII FOLL.ADENO.
17 JEEVA 26 F 385684 THY III FOLL.ADENO.
18 KARUPANNAN 70 M 294089 THY V ANAPLASTIC CA
19 PANJAMMAL 33 F 376598 THY V PAP CA
20 SUMATHY 37 F 377641 THY III FOLL.ADENO.
21 KALANJIYAM 30 F 374221 THY III FOLL.ADENO.
22 VEERAMMAL 52 F 165989 THY IV FOLL.CA.
23 MUTHULAKSHMI 30 F 372434 THY II HASHIMATO'S
24 SUBBULAKSHMI 40 F 371714 THY III FOLL.ADENO.
25 YASMIN 14 F 371075 THY I FOLL.ADENO.
26 VALLI 35 F 151367 THY V PAP CA
27 CHITRAN 60 M 291453 THY V PAP CA
28 DHANALAKSHMI 33 F 365956 THY III FOLL.ADENO.
29 PANCHU 20 F 370529 THY II HASHIMATO'S
30 PONMANI 36 F 144129 THY V PAP CA
31 LAKSHMI 19 F 135693 THY I FOLL.ADENO.
32 MAAREESWARI 30 F 369331 THY II MNG
33 LINGAMMAL 30 F 141706 THY III FOLL.ADENO.
34 KODEESWARI 23 F 141227 THY II PAP CA
35 LOORTHUMARY 42 F 352216 THY III FOLL.CA.
36 KALIMUTHU 40 M 297005 THY III FOLL.ADENO.
37 LAKSHMI 30 F 360685 THY V PAP CA
38 SHANTHI 19 F 360210 THY I FOLL.ADENO.
39 MEENA 30 F 364810 THY III FOLL.ADENO.
40 PONMAARIAMMAL 35 F 365929 THY I PAP CA
41 MEENAKSHI 50 F 355360 THY IV FOLL.CA.
42 BACKIALAKSHMI 35 F 353640 THY III FOLL.ADENO.
43 SEKAR 40 M 310291 THY V PAP CA
44 CHELLAMMAL 55 F 358995 THYIII FOLL.ADENO.
45 MUMTAJ 35 F 100627 THY I SPINDLE CELL SAR.
46 PONNEESWARI 29 F 395318 THYIII FOLL.ADENO.
47 LATHA 33 F 334667 THY V PAP CA
48 AMMAPONNU 48 F 295526 THY V PAP CA
49 RAMUTHAI 50 F 295961 THY I FOLL.ADENO.
50 RAMAMMAL 42 F 395735 THY V PAP CA
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51 PANDIAMMAL 22 F 353608 THY II HASHIMATO'S
52 SELVI 23 F 352035 THY III FOLL.ADENO.
53 PITCHAIAMMAL 18 F 352150 THY II MNG
54 KOLUSAMMAL 35 F 351244 THY III FOLL.ADENO.
55 MAYAKKAL 60 F 352170 THY IV FOLL.CA.
56 KADAMBU 55 M 318209 THY V PAP CA
57 USHA 42 F 944521 THY I FOLL.ADENO.
58 ESWARI 20 F 271348 THY III FOLL.ADENO.
59 PANDIAMMAL 50 F 346025 THY V PAP CA
60 ALFONSA 47 F 346254 THY III FOLL.CA.
61 KAVITHA 26 F 340021 THY I FOLL.ADENO.
62 PERUMAL 56 M 104995 THY IV FOLL.CA.
63 LAKSHMI 38 F 343006 THY IV HASHIMATO'S
64 ROJA 20 F 361684 THY III FOLL.ADENO.
65 PONMALAR 25 F 357363 THY V PAP CA
66 AMARAVATHY 40 F 357149 THY V PAP CA
67 AMINAAMMAL 20 F 357062 THY III FOLL.ADENO.
68 JOTHILAKSHMI 21 F 343013 THY III FOLL.ADENO.
69 VELLAIYAMMAL 39 F 339743 THY III FOLL.CA.
70 GNANAMMAL 55 F 337442 THY V PAP CA
71 MENAKA 25 F 337402 THY I FOLL.ADENO.
72 KAVITHA 25 F 474401 THY II MNG
73 KAALIAMMAL 37 F 335809 THY III FOLL.ADENO.
74 PAVANRAJ 46 M 104086 THY IV MEDULLARY CA.
75 KANAKARATHINAM 67 F 342118 THY III FOLL.ADENO.
76 LAKSHMI 45 F 331684 THY V PAP CA
77 RANJANI 18 F 332690 THY I FOLL.ADENO.
78 SHANTHI 25 F 821139 THY III MNG
79 MARAGADAM 40 F 327915 THY V PAP CA
80 ROZIA BEGUM 55 F 327409 THY III FOLL.ADENO.
81 NATCHAMMAL 25 F 327854 THY V PAP CA
82 LAKSHMI 45 F 326417 THY III FOLL.CA.
83 NATARAJAN 35 M 329065 THY V HASHIMATO'S
84 RATHINAM 35 F 327211 THY V PAP CA
85 SHANTHI 38 F 325861 THY III FOLL.ADENO.
86 PONNAMMAL 19 F 318268 THY I FOLL.ADENO.
87 PANCHAVARNAM 26 F 318279 THY IV HASHIMATO'S
88 PALANISAMY 61 M 371748 THY V PAP CA
89 SUMATHY 27 F 309080 THY III FOLL.ADENO.
90 CHANDRA 32 F 302716 THY III FOLL.ADENO.
91 PUSHPAM 55 F 304787 THY III FOLL.CA.
92 MALLIKA 32 F 302677 THY V PAP CA
93 RENUGADEVI 25 F 269642 THY I FOLL.ADENO.
94 DEVI 36 F 270273 THY V PAP CA
95 RAKKAMMAL 35 F 264774 THY III FOLL.ADENO.
96 KOTHAIAMMAL 46 F 264743 THY II MNG
97 KARUPAYEE 30 F 262936 THY III FOLL.ADENO.
98 MANJAMADEVI 29 F 273799 THY V PAP CA
99 CHELLAMMAL 45 F 271320 THY I FOLL.ADENO.
100 JYOTHI 20 F 275980 THY II HASHIMATO'S
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101 PERIYAKARRUPPAN 32 M 408704 THY III FOLL.ADENO.
102 MURUGESHWARI 23 F 276778 THY V PAP CA
103 MUNIAMMAL 35 F 270191 THY III FOLL.ADENO.
104 AYYAMMAL 60 F 274421 THY IV POORLY DIFF. CA
105 PARAMESHWARI 19 F 277432 THY III FOLL.ADENO.
106 SANTHANALAKSHMI 50 F 278526 THY III FOLL.ADENO.
107 VELU 58 M 426518 THY V PAP CA
108 SUGANYA 31 F 278481 THY II MNG
109 RANI 30 F 282122 THY V PAP CA
110 VADIVAMMAL 30 F 276291 THY I FOLL.ADENO.
111 SUSHEELA 27 F 287882 THY III FOLL.ADENO.
112 RAKKAMMAL 57 F 292392 THY V PAP CA
113 FATHIMA BEEVI 37 F 310728 THY III FOLL.ADENO.
114 KALA 22 F 298217 THY III HASHIMATO'S
115 ASHA DEVI 29 F 294720 THY V PAP CA
116 HELEN 21 F 297219 THY III FOLL.ADENO.
117 SONAI 40 M 526146 THY IV MNG
118 DEVAVINODINI 42 F 222964 THY I FOLL.ADENO.
119 MAYAKKAL 28 F 232924 THY V PAP CA
120 ROJA 20 F 161684 THY III FOLL.ADENO.
121 DURGADEVI 21 F 404073 THY III FOLL.ADENO.
122 LAKSHMANAN 38 M 173471 THY V PAP CA
123 VASANTHA 45 F 390761 THY IV MNG
124 VELLATHAI 65 F 237986 THY IV FOLL.CA.
125 PANDIAMMAL 30 F 241695 THY I FOLL.ADENO.
126 MANJULA 30 F 242104 THY III FOLL.ADENO.
127 CHINAMMAL 43 F 241741 THY IV MEDULLARY CA.
128 VAIRAVALLI 38 F 242384 THY III FOLL.ADENO.
129 VANITHA 18 F 235387 THY III FOLL.ADENO.
130 GEETHA 36 F 323347 THY V PAP CA
131 REVATHY 23 F 247183 THY III FOLL.ADENO.
132 DHANAM 48 F 252309 THY V PAP CA
133 PUSHPAM 37 F 252269 THY I FOLL.ADENO.
134 GANESAN 30 M 290407 THY III FOLL.ADENO.
135 VELLAIYAMMAL 40 F 254166 THY V PAP CA
136 ARUNA 38 F 252728 THY III FOLL.ADENO.
137 VENNILA 20 F 252473 THY III FOLL.ADENO.
138 CHELLAMMAL 55 F 411375 THY IV MNG
139 RAGAVAN 40 M 403443 THY V PAP CA
140 KAATHAMMAL 54 F 416506 THY V PAP CA
141 SATHYA 25 F 270861 THY II FOLL.ADENO.
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S.NO. NAME AGE SEX I.P.NO. SMEAR CATEGORY HPE DIANOSIS SMEAR QUALITY
1 RAJATHI 25 F 411733 THY II MNG DS
2 LEELAVATHY 28 F 412925 THY III FOLL.ADENO. DS
3 JAILANI 40 F 213369 THY V PAP. CA. DS
4 ADAIKIYAMMAL 28 F 291200 THY III FOLL.ADENO. DA
5 AMUTHA 19 F 410929 THY II MNG DS
6 VASANTHA 28 F 233702 THY III FOLL.ADENO. DS
7 POONGKODI 37 F 417450 THY I PAP. CA. UNS
8 MAHALINGAM 68 M 418720 THY V ANAPLASTIC CA. DS
9 ESWARI 24 F 317405 THY III FOLL.ADENO. DS
10 ANNAPOORNI 30 F 418713 THY III FOLL.ADENO. DS
11 SUBBULAKSHMI 40 F 324404 THY V PAP. CA. DA
12  KAALEESWARI 37 F 417449 THY V PAP. CA. DA
13 SUMATHY 18 F 425675 THY III FOLL.ADENO. DS
14 PUSHPALATHA 30 F 421383 THY IV MNG DA
15 NISHA 23 F 310106 THY III FOLL.ADENO. DS
16 SORNALATHA 19 F 311106 THY III FOLL.ADENO. DA
17 PONNUTHAI 40 F 331016 THY V PAP. CA. DS
18 POOMATHY 50 F 429559 THY II FOLL.ADENO. DS
19 MURUGESWARAN 30 M 426982 THY III FOLL.ADENO. DS
20 PREMA 41 F 436572 THY V PAP. CA. DA
21 KAALIATHAL 50 F 436812 THY V PAP. CA. DA
22 MUTHUMARI 28 F 436603 THY II MNG DS
23 AMIRTHAM 45 F 428449 THY III FOLL.CA DA
24 CHINNAMMAL 30 F 239106 THY III FOLL.ADENO. DS
25 JEEVARANI 33 F 432106 THY III FOLL.ADENO. DA
26 RAVICHANDRAN 41 M 381412 THY V PAP. CA. DA
27 POTHIAMMAL 55 F 325106 THY III FOLL.ADENO. DS
28 DHANALAKSHMI 41 F 223106 THY V PAP. CA. DS
29 ALAGAMMAL 35 F 326106 THY III FOLL.CA DA
30 VIJAYALAKSHMI 30 F 527106 THY IV MNG DA
31 MUTHAMMAL 60 F 433856 THY III FOLL.ADENO. DS
32 LAKSHMI 40 F 429996 THY IV MEDULLARY CA DS
33 DHANALAKSHMI 23 F 433853 THY III FOLL.ADENO. DA
34 MURUGAVALLI 35 F 320106 THY V PAP. CA. DA
35 SHANTHY 33 F 344618 THY II MNG DS
36 BALAIAH 48 M 367106 THY IV FOLL.CA DS
37 LAKSHMI 22 F 213106 THY III FOLL.ADENO. DA
38 GANDIMATHY 24 F 242829 THY III FOLL.ADENO. DS
39 MUTHULAKSHMI 38 F 319106 THY V PAP. CA. DA
40 JANAKI 35 F 213806 THY III FOLL.ADENO. DS
41 KAMATCHI 45 F 438181 THY III FOLL.ADENO. DA
42 RAJENDRAN 50 M 372106 THY V POORLY DIFF. CA DS
43 SARANYADEVI 26 F 386550 THY III FOLL.ADENO. DA
44 RAJESHWARI 48 F 431306 THY V PAP. CA. DA
45 PUSHPAVATHY 27 F 273674 THY II MNG DS
46 INDUMATHY 26 F 438677 THY II HASHIMATO'S DS
47 ALAGAMMAL 46 F 276361 THY V PAP. CA. DS
48 MAHALAKSHMI 31 F 890801 THY I MNG UNS
49 JEYALAKSHMI 43 F 439477 THY V PAP. CA. DA
50 SENNAKRISHNAMMAL 40 F 352106 THY V PAP. CA. DA
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51 MEENAKSHI 35 F 378202 THY III FOLL.CA DA
52 SUBBULAKSHMI 34 F 321556 THY III FOLL.ADENO. DS
53 DASS 59 M 329206 THY V PAP. CA. DA
54 SELVI 50 F 350426 THY V PAP. CA. DA
55 KRISHNALEELA 29 F 285392 THY II MNG DS
56 VIJAYALAKSHMI 40 F 360206 THY III FOLL.ADENO. DA
57 ANANDAVALLI 40 F 388464 THY V PAP. CA. DS
58 SHANTHY 30 F 442804 THY II FOLL.ADENO. DS
59 MUTHALAGU 37 F 370206 THY V PAP. CA. DA
60 SATHYA 18 F 169206 THY II HASHIMATO'S DS
61 PANDIAMMAL 35 F 437519 THY V PAP. CA. DA
62 DEVI 70 F 445039 THY IV FOLL.CA DA
63 VIGNESH 18 M 450853 THY II HASHIMATO'S DS
64 KAMATCHI 45 F 438687 THY III FOLL.ADENO. DS
65 RAJESHWARI 40 F 177500 THY V PAP. CA. DA
66 VEERALAKSHMI 40 F 375206 THY V PAP. CA. DA
67 VELLAIYAMMAL 48 F 391123 THY III FOLL.CA DA
68 VEERARAJAMMAL 33 F 390412 THYIII FOLL.ADENO. DS
69 SONAI 65 M 276514 THY V PAP. CA. DA
70 RADHA 22 F 276106 THY III FOLL.ADENO. DS
71 AMEENA 41 F 445145 THY V PAP. CA. DA
72 MUTHURAKKU 22 F 277106 THY II MNG DS
73 NAGARATHINAM 39 F 191062 THY V PAP. CA. DS
74 VIJAYALAKSHMI 45 F 380186 THY III FOLL.ADENO. DA
75 DURAIPANDI 70 M 360158 THY V PAP. CA. DA
76 BANUPRIYA 36 F 448410 THY III FOLL.ADENO. DS
77 FATHIMABEEVI 45 F 190206 THY V PAP. CA. DA
78 ROOPINI 18 F 188206 THY II HASHIMATO'S DS
79 SUSHEELA 30 F 389106 THY III FOLL.ADENO. DA
80 KRISHNAMMAL 70 F 179206 THY V ANAPLASTIC CA. DS
81 GANAPATHY 43 M 282378 THY V MEDULLARY CA DS
82 SIKKARI 35 F 267313 THY III FOLL.ADENO. DA
83 SUNDARI 46 F 268918 THY III FOLL.CA DA
84 MURUGESWARI 40 F 376104 THY III FOLL.ADENO. DS
85 RITA 45 F 271685 THY III FOLL.ADENO. DS
86 NEELAVATHY 40 F 270046 THY V PAP. CA. DA
87 GANDIMATHY 38 F 270005 THY V PAP. CA. DS
88 INDRA 35 F 273651 THY V PAP. CA. DA
89 LAKSHMI 29 F 273816 THY III FOLL.ADENO. DS
90 JEEVAKALA 18 F 275321 THY III FOLL.ADENO. DA
91 PANDI 30 M 297328 THY IV MNG DA
92 PAPPA 32 F 276548 THY III FOLL.ADENO. DA
93 MUNEESWARI 28 F 278828 THY II MNG DS
94 ARUNA 18 F 276784 THY II HASHIMATO'S DS
95 DEVI 24 F 310204 THY II MNG DS
96 SULOCHANA 25 F 369104 THY III FOLL.ADENO. DA
97 DEEPA 28 F 292209 THY II PAP. CA. DA
98 VIJAYA 31 F 300714 THY III FOLL.ADENO. DA
99 RAJAMMAL 59 F 298561 THY IV FOLL.CA DA
100 GLADIUS 23 M 502104 THY III FOLL.ADENO. DA
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101 MALLIKA 52 F 300763 THY V PAP. CA. DS
102 CHITRADEVI 29 F 304026 THY III FOLL.ADENO. DA
103 DURGA 33 F 292149 THY V PAP. CA. DA
104 MAARIAMMAL 65 F 292159 THY IV POORLY DIFF. CA DS
105 ANTHONYAMMAL 54 F 294041 THY IV FOLL.CA DA
106 UMA MAHESHWARI 29 F 301935 THY II FOLL.ADENO. DS
107 MARIAMMAL 20 F 309565 THY III FOLL.ADENO. DA
108 MUTHUSAMY 40 M 350104 THY V MNG DA
109 DEEPA 23 F 283827 THY III FOLL.ADENO. DS
110 MALAR 21 F 219558 THY IV HASHIMATO'S DA
111 JEYASUDHA 25 F 283814 THY III FOLL.ADENO. DS
112 AYYAMMAL 45 F 283793 THY V PAP. CA. DA
113 MUTHURAKKU 18 F 278849 THY I FOLL.ADENO. UNS
114 DURGADEVI 40 F 310104 THY III FOLL.ADENO. DA
115 RAMALINGAM 45 M 501064 THY V PAP. CA. DA
116 CHANDRA 33 F 319910 THY III FOLL.ADENO. DA
117 TIRUPATHI 22 F 270860 THY II MNG DS
118 PUSHPALATHA 28 F 311248 THY II MNG DS
119 LOORTHUMARY 55 F 226484 THY III FOLL.ADENO. DA
120 DHANAM 35 F 211360 THY V PAP. CA. DS
121 MURUGESWARI 22 F 417140 THY III FOLL.ADENO. DA
122 ABDUL KADAR 60 M 268132 THY IV FOLL.CA DA
123 ESWARI 25 F 417034 THY III FOLL.ADENO. DS
124 VASUKI 32 F 316948 THY V PAP. CA. DA
125 PITCHAIAMMAL 58 F 317242 THY IV FOLL.CA DS
126 MURUGAN 30 M 387921 THY III FOLL.ADENO. DA
127 RAJESHWARI 41 F 227630 THY V PAP. CA. DA
128 SHANTHY 38 F 171710 THY V PAP. CA. DA
129 SHAKILA BEGUM 32 F 484690 THY III FOLL.ADENO. DS
130 MUNEESHWARI 23 F 584671 THY III FOLL.ADENO. DA
131 SHANTHY 22 F 134463 THY II MNG DS
132 RANI 26 F 729001 THY II MNG DS
133 MALLIKA 25 F 526361 THY III FOLL.ADENO. DA
134 MAHESHWARI 37 F 261800 THY IV MEDULLARY CA DS
135 RAJESHWARI 40 F 582471 THY V PAP. CA. DA
136 BACKIALAKSHMI 41 F 580991 THY V HASHIMATO'S DA
137 SAVUDAMOORTHY 40 M 350193 THY III FOLL.CA DA
138 VALLI 58 F 520823 THY IV FOLL.CA DS
139 LEELAVATHY 29 F 175639 THY III FOLL.ADENO. DA
140 MURUGESWARI 32 F 486001 THY IV PAP. CA. DA
141 NAGAMANI 26 F 485190 THY III FOLL.ADENO. DA
142 ALAGU 40 F 260444 THY V PAP. CA. DA
143 MATCHADEVI 30 F 435910 THY III FOLL.ADENO. DA
144 SUBRAMANI 35 M 260158 THY V PAP. CA. DA
145 THERESA 39 F 323241 THY III FOLL.ADENO. DA
146 JEYACHITRA 19 F 325581 THY II MNG DS
147 VALARMATHI 24 F 332291 THY III FOLL.ADENO. DS
148 PRABHA 28 F 330412 THY III FOLL.ADENO. DA
